Athira Pharma Inc

NASDAQ:ATHAUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.

Contact Information

Headquarters

18706 North Creek Parkway Suite 104, Box 352141BOTHELL, WA, United States 98011

Phone

425-620-8501

Fax

302-636-5454

Executives

Independent Chairwoman of the Board

Kelly Romano

President, Chief Executive Officer, Director

Mark Litton

Principal Financial Officer and Principal Accounting Officer

Robert Renninger

Chief People Officer

Samantha Willing

Chief Scientific Officer

Kevin Church